Home / Letter From The Editor / Sept. 1, 2020

Sept. 1, 2020

Sep 1, 2020

Melinda Rodriguez, PharmD Candidate 2021, Lake Erie College of Osteopathic Medicine, is attempting to help us understand the concept of Biosimilars. Her drug class of choice to unravel the process is insulin. In her feature this week she looks at the radical changes the FDA has to make to allow the almost, but not quite, duplication of the branded product.

As this trend continues, it will be interesting to see if lower insulin prices will become the norm, or will PBM’s keep these products off formularies so they can get their branded rebates?




We can make a difference!


Dave Joffe